TELA Bio, Inc. (TELA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex (hernia repair) and OviTex PRS (plastic and reconstructive surgery) product portfolios. The company operates as a single reportable segment and relies on an exclusive contract manufacturer, Aroa Biosurgery Ltd., for its core products.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $19.3 million | $38.4 million | $20.2 million | $38.7 million |
| Gross Profit | $13.9 million | $26.5 million | $14.1 million | $26.6 million |
| Gross Margin | 72% | 69% | 70% | 69% |
| Net Loss | $(11.3) million | $(23.5) million | $(9.9) million | $(21.2) million |
| Diluted EPS | $(0.20) | $(0.41) | $(0.22) | $(0.47) |
| Cash & Equivalents | $30.4 million | (As of June 30, 2026) | ||
| Long-Term Debt | $56.1 million | (Net of issuance costs) | ||
| Working Capital | $36.3 million | (Current Assets $54.5M - Current Liab $18.2M) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4% QoQ and 1% YTD compared to 2025. This was driven by a 23% decline in OviTex PRS unit sales and price mix headwinds in the U.S. due to a shift toward smaller unit sizes. These declines were partially offset by a 12% increase in OviTex unit sales and growth in international sales.
- Increased Interest Expense: Interest expense rose 75% QoQ and 72% YTD due to the new Perceptive Credit Agreement (funded Nov 2025), which carries a higher interest rate and principal balance compared to the prior MidCap facility.
- Operating Expenses: Sales and marketing expenses decreased slightly (2% QoQ) due to reduced headcount. Research and development expenses increased 24% QoQ due to higher study costs and additional headcount.
- Liquidity Position: Cash and cash equivalents decreased from $50.8 million at year-end 2025 to $30.4 million at June 30, 2026, reflecting a net cash burn of $20.5 million from operating activities over the first half of the year.
Guidance, Outlook, and Risks
Going Concern Warning: Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of this report. While compliant with covenants as of June 30, 2026, current forecasts indicate the Company will likely fail to meet the minimum revenue threshold required under its Credit Agreement with Perceptive in future quarters.
Debt Covenants: The Perceptive Term Loan Facility ($60M outstanding) requires maintaining minimum liquidity of $5.0 million and specific revenue thresholds. Failure to meet these covenants without a waiver could trigger an event of default, accelerating repayment of the full principal and accrued interest, which the Company lacks the liquidity to repay.
Management Actions: The Company is pursuing a waiver or amendment to the revenue covenant, implementing cost-reduction measures, and seeking strategic initiatives to increase revenue.
Other Risks: The filing highlights risks related to a 12.5% U.S. tariff on imports from New Zealand (shared with the manufacturer), potential supply chain disruptions for critical surgical supplies, and macroeconomic pressures affecting hospital spending.
Investor Verification Checklist
- Covenant Compliance: Verify the specific revenue thresholds required by the Perceptive Credit Agreement and the Company's current trajectory to meet them.
- Waiver Status: Confirm if a waiver or amendment to the revenue covenant has been secured from Perceptive Credit Holdings V, LP.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate (~$20.5M in 6 months) against the remaining cash balance of $30.4M.
- Product Mix Trends: Monitor the continued decline in OviTex PRS sales volume and the impact of the shift to smaller unit sizes on overall revenue.
- Tariff Impact: Evaluate the financial impact of the 12.5% tariff on New Zealand imports and whether pricing adjustments are being implemented to offset these costs.